How accurate is your prognostic test? The TransATAC study compared the performance of four commercially available prognostic signatures for prediction of breast cancer distant recurrence.
Among both first and second generation tests, the EndoPredict® Breast Cancer Prognostic Test was the best prognostic signature in predicting distant recurrence in years 0-10 and in years 5-10 in patients with node negative or node positive disease. It also accurately identified the largest group of patients at low-risk of recurrence who could avoid chemotherapy.
Fill out the form below to download your free copy of the clinical summary to learn more about this key study.